Related Experiment Video
Updated: Feb 16, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Frequent methylation of DAB2, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas
Jaroslaw Paluszczak1, Katarzyna Kiwerska2, Daniela Mielcarek-Kuchta3
1Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Poznan, Poland.
Background:
Aberrations in Wnt signaling pathway are related to the pathogenesis of head and neck carcinomas and their activation frequently results from epigenetic alterations. This study aimed to assess the frequency of the methylation of DAB2, which acts as a negative regulator of Wnt signaling, and correlate it with clinicopathological features in a group of oral cancer patients.
Material And Methods:
Forty nine patients with primary oral squamous cell carcinoma were enrolled in the study. DNA samples were isolated from surgical sections using phenol-chloroform extraction. Methylation-specific PCR was used to detect gene promoter methylation.
Results:
The analysis of the occurrence of DAB2 promoter methylation in primary oral carcinomas indicated that the gene is methylated in 70% of cases. However, no correlation was found between its methylation and TNM staging or overall survival.
Conclusions:
Our findings corroborate that DAB2 is a frequent target of epigenetic silencing in oral carcinomas and may be potentially used for tumor detection.
Insights
DAB2 gene promoter methylation is frequent in oral cancer, occurring in 70% of cases. This epigenetic silencing may offer potential for early tumor detection, though not linked to staging or survival.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Aberrant Wnt signaling is implicated in head and neck carcinomas.
- Epigenetic alterations frequently drive Wnt pathway activation.
- DAB2 negatively regulates Wnt signaling.
Purpose of the Study:
- Assess the frequency of DAB2 promoter methylation in oral cancer.
- Correlate DAB2 methylation with clinicopathological features.
- Investigate DAB2 as a potential biomarker for oral carcinoma.
Main Methods:
- Study included 49 patients with primary oral squamous cell carcinoma.
- DNA extracted from surgical specimens via phenol-chloroform method.
- Methylation-specific PCR used for gene promoter methylation analysis.
Main Results:
- DAB2 promoter methylation detected in 70% of primary oral carcinomas.
- No significant correlation found between DAB2 methylation and TNM staging.
- DAB2 methylation status did not correlate with overall patient survival.
Conclusions:
- DAB2 is frequently epigenetically silenced in oral carcinomas.
- Epigenetic silencing of DAB2 is a common event in oral carcinogenesis.
- DAB2 may serve as a potential biomarker for oral tumor detection.
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Canonical Wnt Signaling Pathway
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Non-Canonical Wnt Signaling Pathways

